Učitavanje...

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease

Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to reverse the bone deficit in patients. Bortezomib, a proteasome inhibitor with antitumour efficacy in myeloma patients, enhanced new bone formation in mo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Br J Haematol
Glavni autori: Oyajobi, Babatunde O., Garrett, I. Ross, Gupta, Anjana, Flores, Alda, Esparza, Javier, Muñoz, Steve, Zhao, Ming, Mundy, Gregory R.
Format: Artigo
Jezik:Inglês
Izdano: 2007
Teme:
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4482356/
https://ncbi.nlm.nih.gov/pubmed/17910634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2141.2007.06829.x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!